Generic Drug Bioequivalence Study Interruptions Not Just A Coronavirus Problem

 
• By Derrick Gingery
PCR strip test tubes and micropipette in genetics laboratory. Toned photo
Generic drug sponsors are looking for help from the FDA to "save" bioequivalence studies interrupted by coronavirus or other problems. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics